MRK Overview
Upcoming Projects (MRK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MRK)
-
A Third Look: Discussing the potential of Tulisokibart (MK-7240) and SPY001, an investigational anti-TL1A monoclonal antibody being developed for the management of IBD.
Tickers: MRK, SYRE
Executed On: Dec 19, 2024 at 03:30 PM EST -
A Third Look: Investigating the data from the Phase 3 ZENITH clinical trial of Winrevair (Sotatercept-csrk) in patients with PAH.
Ticker: MRK
Executed On: Dec 19, 2024 at 02:00 PM EST -
A Second Look: Investigating the data from the Phase 3 ZENITH clinical trial of Winrevair (Sotatercept-csrk) in patients with PAH.
Ticker: MRK
Executed On: Dec 19, 2024 at 12:00 PM EST -
Investigating the data from the Phase 3 ZENITH clinical trial of Winrevair (Sotatercept-csrk) in patients with PAH.
Ticker: MRK
Executed On: Dec 05, 2024 at 10:00 AM EST -
A Second Look: Discussing the potential of Tulisokibart (MK-7240) and SPY001, an investigational anti-TL1A monoclonal antibody being developed for the management of IBD.
Tickers: MRK, SYRE
Executed On: Nov 20, 2024 at 04:00 PM EST -
Discussing the potential of Tulisokibart (MK-7240) and SPY001, an investigational anti-TL1A monoclonal antibody being developed for the management of IBD.
Tickers: MRK, SYRE
Executed On: Nov 19, 2024 at 06:05 PM EST -
Discussing the potential of Capvaxive (V116) a 21-valent conjugate vaccine from Merck that was recently approved by the FDA for the prevention of pneumococcal disease in adults over the age of 50.
Ticker: MRK
Executed On: Jul 16, 2024 at 10:00 AM EDT -
A Second Opinion: Discussing the data for vibostolimab coformulated with pembrolizumab (vibo/pembro) for treatment of advanced mismatch repair–deficient (dMMR) endometrial cancer presented ASCO 2024
Ticker: MRK
Executed On: Jun 07, 2024 at 09:15 AM EDT -
Discussing the data for vibostolimab coformulated with pembrolizumab (vibo/pembro) for treatment of advanced mismatch repair–deficient (dMMR) endometrial cancer presented ASCO 2024
Ticker: MRK
Executed On: Jun 05, 2024 at 03:00 PM EDT -
A Third Look: Perusing the 21-Valent Pneumococcal Conjugate Vaccine V116 from Merck
Ticker: MRK
Executed On: May 09, 2024 at 10:45 AM EDT -
A Second Look: Perusing the 21-Valent Pneumococcal Conjugate Vaccine V116 from Merck
Ticker: MRK
Executed On: May 08, 2024 at 05:15 PM EDT -
Perusing the 21-Valent Pneumococcal Conjugate Vaccine V116 from Merck
Ticker: MRK
Executed On: May 08, 2024 at 11:00 AM EDT -
A Third Look: Investigating the phase 3 clinical trial results of Merck's sotatercept for patients with pulmonary arterial hypertension.
Ticker: MRK
Executed On: Mar 27, 2024 at 12:00 PM EDT -
A Second Look: Investigating the phase 3 clinical trial results of Merck's sotatercept for patients with pulmonary arterial hypertension.
Ticker: MRK
Executed On: Mar 21, 2024 at 01:00 PM EDT -
Investigating the phase 3 clinical trial results of Merck's sotatercept for patients with pulmonary arterial hypertension.
Ticker: MRK
Executed On: Mar 07, 2024 at 06:00 PM EST -
A Third Opinion: Discussing the mental health side effects and the use of Singulair (montelukast) for treating pediatric asthma.
Tickers: OGN, MRK
Executed On: Feb 21, 2024 at 05:00 PM EST -
Discussing the potential of Astellas Pharma's Padcev (enfortumab vedotin-ejfv) in combo with Merck’s Keytruda (pembrolizumab), as a recently approved treatment option for patients with urothelial cancer.
Tickers: SGEN, MRK
Executed On: Feb 07, 2024 at 12:00 PM EST -
A Second Opinion: Discussing the mental health side effects and the use of Singulair (montelukast) for treating pediatric asthma.
Tickers: OGN, MRK
Executed On: Feb 01, 2024 at 10:00 AM EST -
Discussing the mental health side effects and the use of Singulair (montelukast) for treating pediatric asthma.
Tickers: OGN, MRK
Executed On: Jan 18, 2024 at 03:00 PM EST -
A Third View: Exploring the Phase 3 KEYNOTE-564 clinical trial data of KEYTRUDA (pembrolizumab) in patients with renal cell carcinoma.
Ticker: MRK
Executed On: Jan 09, 2024 at 02:00 PM EST -
A Second View: Exploring the Phase 3 KEYNOTE-564 clinical trial data of KEYTRUDA (pembrolizumab) in patients with renal cell carcinoma.
Ticker: MRK
Executed On: Jan 04, 2024 at 06:30 PM EST -
A Third Look: Investigating the Phase 3 STRIDE-3 Clinical trial data on V116 presented at World Vaccine Congress West Coast
Ticker: MRK
Executed On: Dec 12, 2023 at 04:00 PM EST -
A Second Look: Investigating the Phase 3 STRIDE-3 Clinical trial data on V116 presented at World Vaccine Congress West Coast
Ticker: MRK
Executed On: Dec 12, 2023 at 08:30 AM EST -
Investigating the Phase 3 STRIDE-3 Clinical trial data on V116 presented at World Vaccine Congress West Coast
Ticker: MRK
Executed On: Dec 08, 2023 at 04:00 PM EST -
Exploring the Phase 3 KEYNOTE-564 clinical trial data of KEYTRUDA (pembrolizumab) in patients with renal cell carcinoma.
Ticker: MRK
Executed On: Dec 07, 2023 at 05:30 PM EST -
A Second View: Investigating the phase III clinical trial results of enfortumab vedotin in combination with pembrolizumab presented at ESMO 2023
Tickers: SGEN, MRK
Executed On: Nov 06, 2023 at 02:00 PM EST -
Investigating the phase III clinical trial results of enfortumab vedotin in combination with pembrolizumab presented at ESMO 2023
Tickers: SGEN, MRK
Executed On: Nov 02, 2023 at 03:00 PM EDT -
A Third Look: Discussing the standard of care and/or the potential of Merck's efinopegdutide (MK-6024) in patients with NAFLD
Ticker: MRK
Executed On: Sep 20, 2023 at 11:00 AM EDT -
A third look at the potential use of Merck's gefapixant in anticipation of the FDA Adcom review which was previously rejected by the FDA
Ticker: MRK
Executed On: Sep 19, 2023 at 01:00 PM EDT -
A second look at the potential use of Merck's gefapixant in anticipation of the FDA Adcom review which was previously rejected by the FDA
Ticker: MRK
Executed On: Sep 18, 2023 at 02:00 PM EDT -
A look at the potential use of Merck's gefapixant in anticipation of the FDA Adcom review which was previously rejected by the FDA
Ticker: MRK
Executed On: Sep 14, 2023 at 03:00 PM EDT -
A Second Look: Discussing the standard of care and/or the potential of Merck's efinopegdutide (MK-6024) in patients with NAFLD
Ticker: MRK
Executed On: Sep 06, 2023 at 06:15 PM EDT -
Discussing the standard of care and/or the potential of Merck's efinopegdutide (MK-6024) in patients with NAFLD
Ticker: MRK
Executed On: Aug 31, 2023 at 08:00 AM EDT -
Discussing the recent results from the phase 3 KEYNOTE-A18 trial, studying Merck's Keytruda in combination with EBRT and chemotherapy followed by brachytherapy, for patients with cervical cancer.
Ticker: MRK
Executed On: Aug 10, 2023 at 10:00 AM EDT -
Discussing the potential of Merck's V116 pneumococcal vaccine candidate along with the clinical data from the STRIDE phase 3 trials reviewing V116 for the prevention of invasive pneumococcal disease
Ticker: MRK
Executed On: Aug 02, 2023 at 02:30 PM EDT -
Discussing the standard of care for prostate cancer and the recent approval of Lynparza for metastatic castration-resistant prostate cancer (mCRPC).
Tickers: AZN, MRK
Executed On: May 30, 2023 at 02:30 PM EDT -
A second look: Discussing the potential of mRNA-4157, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor, pembrolizumab, for patients with high-risk melanoma
Tickers: MRNA, MRK
Executed On: May 04, 2023 at 06:00 PM EDT -
Discussing the potential of mRNA-4157, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor, pembrolizumab, for patients with high-risk melanoma
Tickers: MRK, MRNA
Executed On: May 03, 2023 at 10:00 AM EDT -
Discussing the recent approval of Zynyz (Retifanlimab) from Incyte in merkel cell carcinoma (MCC).
Tickers: MRK, INCY
Executed On: Apr 18, 2023 at 02:00 PM EDT -
A second look: Discussing recent advancements and use of synthetic lethality based cancer therapeutics and areas for future development.
Tickers: IDYA, MRK, AZN
Executed On: Mar 21, 2023 at 01:00 PM EDT -
A second look: Delving into the STELLAR Phase III trial of sotatercept by Merck for the treatment of pulmonary arterial hypertension (PAH) released at ACC2023
Ticker: MRK
Executed On: Mar 17, 2023 at 04:15 PM EDT -
Discussing recent advancements and use of synthetic lethality based cancer therapeutics and areas for future development.
Tickers: IDYA, AZN, MRK
Executed On: Mar 16, 2023 at 04:30 PM EDT -
A third look: Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 14, 2023 at 07:00 PM EDT -
A second look: Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 14, 2023 at 06:00 PM EDT -
Delving into the STELLAR Phase III trial of sotatercept by Merck for the treatment of pulmonary arterial hypertension (PAH) released at ACC2023
Ticker: MRK
Executed On: Mar 13, 2023 at 05:00 PM EDT -
Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 13, 2023 at 04:00 PM EDT -
A second examination of the clinical landscape of renal disease and the potential of anticoagulant therapies in this space for the prevention of cardiovascular events, including Merck's MK-2060.
Ticker: MRK
Executed On: Oct 03, 2022 at 03:00 PM EDT -
Examining the clinical landscape of renal disease and the potential of anticoagulant therapies in this space for the prevention of cardiovascular events, including Merck's MK-2060.
Tickers: MRK, PFE, BMY
Executed On: Oct 03, 2022 at 02:00 PM EDT -
An international look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Sep 01, 2022 at 12:45 PM EDT -
A third look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Aug 31, 2022 at 10:00 AM EDT -
A second look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Aug 29, 2022 at 03:00 PM EDT -
A look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Aug 25, 2022 at 05:15 PM EDT -
Discussing Welireg(Belzutifan) as a treatment in patients with von Hippel-Lindau (VHL) disease with associated renal cell carcinoma 1st look
Ticker: MRK
Executed On: Mar 03, 2022 at 11:15 AM EST -
Discussing early clinical experience prescribing Verquvo (Vericiguat) to patients with chronic heart failure
Ticker: MRK
Executed On: Feb 17, 2022 at 05:00 PM EST -
A Third View: Discussing the future of COVID vaccination (the current COVID vaccines, use of boosters, and new vaccines on the horizon.)
Tickers: PFE, MRK
Executed On: Jan 27, 2022 at 12:00 PM EST -
A Second Look: Discussing the future of COVID vaccination (the current COVID vaccines, use of boosters, and new vaccines on the horizon.)
Tickers: PFE, MRK
Executed On: Jan 25, 2022 at 10:00 AM EST -
Discussing the future of COVID vaccination (the current COVID vaccines, use of boosters, and new vaccines on the horizon.)
Tickers: PFE, MRK
Executed On: Jan 19, 2022 at 09:30 AM EST
Upcoming & Overdue Catalysts (MRK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (MRK)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
